Potential new therapeutics for Waldenstrom's macroglobulinemia
- PMID: 12720152
- DOI: 10.1053/sonc.2003.50078
Potential new therapeutics for Waldenstrom's macroglobulinemia
Abstract
Thalidomide the first commercially available immune modulatory drug (IMiD), has activity in the treatment of Waldenstrom's macroglobulinemia (WM), as well as multiple myeloma, myelodysplastic syndrome, myelofibrosis with myeloid metaplasia, chronic lymphocytic leukemia (CLL), and B-cell lymphomas. Although its molecular mechanisms of action have not yet been elucidated, thalidomide and the IMiDs affect a variety of cytokines and inflammatory mediators including tumor necrosis factor-alpha (TNFalpha), interleukin (IL)-1beta, interferon gamma (IFNgamma), IL-6, IL-10, IL-12, and COX-2 and angiogenesis factors such as vascular endothelial growth factor (VEGF) and its receptor. The IMiDs also affect adhesion molecules such as ICAM-1, ICAM-2, and L-CAM, in addition to preferentially stimulating CD8 cells and expanding natural killer (NK) cell populations. Since most IMiDs share these properties, it would be expected that the second-generation IMiDs (REVIMID, ACTIMID) would have activity similar to thalidomide in WM with an improved safety profile. TNFalpha and angiogenesis most likely play a role in promoting the growth and development of WM. The selective cytokine inhibitory drugs (SelCIDs) are potent phosphodiesterase 4 (PDE-4) inhibitors that inhibit TNFalpha production and are highly antiangiogenic. In addition, inhibition of PDE-4 induces apoptosis in human CLL lymphocytes. It is therefore expected that the SelCIDs might have activity in Waldenstrom's tumors. Jun N-terminal kinase (JNK) is a component of signaling cascades that modulate apoptosis, the induction of an inflammatory response via the AP-1 pathway, and modulation of cellular proliferation. In a variety of tumors, including multiple myeloma, JNK is induced as part of a protective mechanism. It is hypothesized that inhibition of JNK activity might allow other chemotherapeutic agents to be more effective in a similar manner to corticosteroids. Work is in progress to evaluate this. Inhibitors of the E3 subunit of ubiquitin ligase may also selectively modulate the expression of receptors, growth factors, and transcription factors essential to the growth, survival, and spread of tumors. We hypothesize that the IMiDs, SelCIDs, JNK inhibitors, and ligase inhibitors will be the basis for a new nonchemotherapeutic approach to the treatment of WM and other related diseases.
Copyright 2003 Elsevier Inc. All rights reserved.
Similar articles
-
Novel therapies targeting the myeloma cell and its bone marrow microenvironment.Semin Oncol. 2001 Dec;28(6):607-12. doi: 10.1016/s0093-7754(01)90033-8. Semin Oncol. 2001. PMID: 11740818 Review.
-
Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs.J Pharmacol Exp Ther. 2003 Jun;305(3):1222-32. doi: 10.1124/jpet.102.048496. Epub 2003 Mar 20. J Pharmacol Exp Ther. 2003. PMID: 12649301
-
[Thalidomide: mechanisms of action and new insights in hematology].Rev Med Interne. 2005 Feb;26(2):119-27. doi: 10.1016/j.revmed.2004.06.017. Rev Med Interne. 2005. PMID: 15710258 Review. French.
-
Novel biologically based therapies for Waldenstrom's macroglobulinemia.Semin Oncol. 2003 Apr;30(2):309-12. doi: 10.1053/sonc.2003.50065. Semin Oncol. 2003. PMID: 12720159 Review.
-
Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.Clin Cancer Res. 2011 Apr 1;17(7):1753-64. doi: 10.1158/1078-0432.CCR-10-2130. Epub 2011 Feb 25. Clin Cancer Res. 2011. PMID: 21355079
Cited by
-
Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.J Transl Med. 2013 Sep 17;11:213. doi: 10.1186/1479-5876-11-213. J Transl Med. 2013. PMID: 24040940 Free PMC article.
-
Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.Acta Biochim Biophys Sin (Shanghai). 2014 Mar;46(3):240-53. doi: 10.1093/abbs/gmt142. Epub 2013 Dec 29. Acta Biochim Biophys Sin (Shanghai). 2014. PMID: 24374776 Free PMC article. Review.
-
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.Blood. 2006 Nov 15;108(10):3458-64. doi: 10.1182/blood-2006-04-015909. Epub 2006 Jul 13. Blood. 2006. PMID: 16840727 Free PMC article. Clinical Trial.
-
Thalidomide and rituximab in Waldenstrom macroglobulinemia.Blood. 2008 Dec 1;112(12):4452-7. doi: 10.1182/blood-2008-04-150854. Epub 2008 Aug 19. Blood. 2008. PMID: 18713945 Free PMC article. Clinical Trial.
-
Monocyte-Derived Dendritic Cells Differentiated in the Presence of Lenalidomide Display a Semi-Mature Phenotype, Enhanced Phagocytic Capacity, and Th1 Polarization Capability.Front Immunol. 2018 Jun 13;9:1328. doi: 10.3389/fimmu.2018.01328. eCollection 2018. Front Immunol. 2018. PMID: 29951065 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous